Prostate-specific membrane antigen PET-CT before radical treatment

Affiliations

Comment

Caroline Moore. Lancet. 2020.

. 2020 Apr 11;395(10231):1170-1172.

doi: 10.1016/S0140-6736(20)30527-4. Epub 2020 Mar 22.

¹ Urology Department, University College London, London WC1E 6BT, UK. Electronic address: caroline.moore@ucl.ac.uk.

No abstract available

Comment on

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Hofman MS, et al. Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22. Lancet. 2020. PMID: 32209449 Clinical Trial.